Pharmesis International (SGX:BFK) Other Stockholders Equity: S$-0.25 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:BFK Pharmesis International Ltd SGX:BFK
33 GF Score
Price S$0.13
GF Value S$0.09
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Pharmesis International Other Stockholders Equity?

Pharmesis International SGX:BFK 33 Other Stockholders Equity is S$-0.25 Mil as of Dec. 2025. GuruFocus rates SGX:BFK with a GF Score™ of 33/100 and a GF Value™ of S$0.09 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Pharmesis International's Other Stockholders Equity for the quarter that ended in Dec. 2025 was S$-0.25 Mil.

Pharmesis International's quarterly Other Stockholders Equity increased from Dec. 2024 (S$-0.25 Mil) to Jun. 2025 (S$-0.24 Mil) but then declined from Jun. 2025 (S$-0.24 Mil) to Dec. 2025 (S$-0.25 Mil).

Pharmesis International's annual Other Stockholders Equity declined from Dec. 2023 (S$0.28 Mil) to Dec. 2024 (S$-0.25 Mil) but then increased from Dec. 2024 (S$-0.25 Mil) to Dec. 2025 (S$-0.25 Mil).

Pharmesis International Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Pharmesis International's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmesis International Other Stockholders Equity Chart

Pharmesis International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.29 0.28 -0.25 -0.25

Pharmesis International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.28 -0.25 -0.24 -0.25
SGX:BFK
33GF Score
Pharmesis International Ltd SGX:BFK
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmesis International Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of S$-0.25 Mil mean?
Pharmesis International (SGX:BFK) has a Other Stockholders Equity of S$-0.25 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Pharmesis International and its competitors.
Is Pharmesis International's Other Stockholders Equity too high?
Pharmesis International's current Other Stockholders Equity is S$-0.25 Mil. Overall, Pharmesis International has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Other Stockholders Equity compare to ZTS and UTHR?
Pharmesis International's Other Stockholders Equity of S$-0.25 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Pharmesis International and its competitors. Pharmesis International's current Other Stockholders Equity is S$-0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.13 — trading 38.9% above its estimated fair value. The current Other Stockholders Equity is S$-0.25 Mil. Pharmesis International's overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Other Stockholders Equity is S$-0.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmesis International (SGX:BFK) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued. The current stock price of S$0.13 is trading 38.9% above its estimated GF Value™ of S$0.09. GuruFocus considers Pharmesis International to be Significantly Overvalued.

Key valuation signals for SGX:BFK:

  • Other Stockholders Equity: S$-0.25 Mil
  • GF Value™: S$0.09 vs. price of S$0.13 (38.9% above fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmesis International Business Description

Address 5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
33GF Score

Get the complete analysis for SGX:BFK

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.13
Price
S$0.09
GF Value